FACET BIOTECH CORP Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 3 Calls Today's Calls

Call Details FACET BIOTECH CORP Earnings Conference Call (Q3 2009) Tue, Nov 3, 2009, 4:30 pm Eastern Listen to the archived event audio About FACET BIOTECH CORP (NasdaqGM:FACT) Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology therapeutics. Its products in development include Daclizumab, a monoclonal antibody in Phase II clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, which is in Phase I/II clinical studies is a chimeric monoclonal antibody that inhibits the functional activity of a protein in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody in Phase I clinical study, which binds to a cell surface glycoprotein that is expressed on myeloma cells and normal human cells; PDL192, a monoclonal antibody in Phase I clinical study, which binds to the tumor necrosis factor-like weak inducer of apoptosis receptor; and PDL241, a monoclonal antibody in the preclinical stage for immunologic diseases. Facet Biotech Corporation has a collaboration agreement with Biogen Idec Inc. The company is headquartered in Redwood City, California. Facet Biotech Corporation operates independently of PDL BioPharma Inc. as of December 18, 2008. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Insider | Financials | Analyst Ratings